本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Neurosense Therapeutics Ltd

0.7700
+0.04005.48%
盤前0.80990.0399+5.18%08:59 EDT
成交量:14.42萬
成交額:10.93萬
市值:2,571.54萬
市盈率:-2.04
高:0.7838
開:0.7100
低:0.7100
收:0.7300
52周最高:2.60
52周最低:0.6300
股本:3,339.66萬
流通股本:2,210.79萬
量比:0.63
換手率:0.65%
股息:- -
股息率:- -
每股收益(TTM):-0.3778
每股收益(LYR):-0.5489
淨資產收益率:-2478.16%
總資產收益率:-303.90%
市淨率:-49.55
市盈率(LYR):-1.40

資料載入中...

2023/04/05

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/03/22

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/03/15

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/03/15

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/03/15

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/01/26

SEC問詢函

CORRESP [Cover] - Correspondence
2022/04/14

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/02

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2021/12/30

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/12/23

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/12/20

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/12/06

SEC問詢函

CORRESP [Cover] - Correspondence
2021/12/06

SEC問詢函

CORRESP [Cover] - Correspondence
2021/12/06

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/12/06

[補充]招股説明書

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/11/19

SEC問詢函

CORRESP [Cover] - Correspondence
2021/11/19

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/11/10

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/11/10

[補充]招股説明書

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/11/04

SEC問詢函

CORRESP [Cover] - Correspondence